Peng-ju Chen, M.D. • Tian-le Li, M.D. • Ting-ting Sun, M.M.S. • Van C. Willis, Ph.D. • M. Christopher Roebuck, Ph.D. • Dena M. Bravata, M.D., M.S. • Xin-zhi Liu, M.D. • Yull Edwin Arriaga, M.D. • Irene Dankwa-Mullan, M.D., M.P.H. • Ai-wen Wu, M.D.
Watson for Oncology produced therapeutic options highly concordant with human decisions at a top-tier cancer center in China. Treatment patterns suggest that Watson for Oncology may be able to guide clinicians to minimize overtreatment of patients with high-risk stage II colon cancer with chemotherapy. Survival analyses suggest the need for further investigation to specifically assess the association between surveillance, single-agent and multiagent chemotherapy, and survival outcomes in this population.